Department of Otolaryngology and Head and Neck Surgery, NHS Lothian, Edinburgh, UK.
Department of Anaesthesia, NHS Lothian, Edinburgh, UK.
J Laryngol Otol. 2021 Jan;135(1):86-87. doi: 10.1017/S0022215120002753. Epub 2021 Jan 7.
Since the start of the coronavirus disease 2019 pandemic, transnasal humidified rapid-insufflation ventilatory exchange ('THRIVE') has been classified as a high-risk aerosol-generating procedure and is strongly discouraged, despite a lack of conclusive evidence on its safety.
This study aimed to investigate the safety of transnasal humidified rapid-insufflation ventilatory exchange usage and its impact on staff members. A prospective study was conducted on all transnasal humidified rapid-insufflation ventilatory exchange cases performed in our unit between March and July 2020.
During the study period, 18 patients with a variety of airway pathologies were successfully managed with transnasal humidified rapid-insufflation ventilatory exchange. For each case, 7-10 staff members were present. Appropriate personal protective equipment protocols were strictly implemented and adhered to. None of the staff involved reported symptoms or tested positive for coronavirus disease 2019, up to at least a month following their exposure to transnasal humidified rapid-insufflation ventilatory exchange.
With strictly correct personal protective equipment use, transnasal humidified rapid-insufflation ventilatory exchange can be safely employed for carefully selected patients in the current pandemic, without jeopardising the health and safety of the ENT and anaesthetic workforce.
自 2019 年冠状病毒病大流行开始以来，经鼻高流量湿化氧疗通气交换（“THRIVE”）被归类为高风险气溶胶产生程序，尽管缺乏关于其安全性的明确证据，但仍强烈不鼓励使用。
本研究旨在调查经鼻高流量湿化氧疗通气交换使用的安全性及其对工作人员的影响。对 2020 年 3 月至 7 月期间在我科进行的所有经鼻高流量湿化氧疗通气交换病例进行了前瞻性研究。
在研究期间，通过经鼻高流量湿化氧疗通气交换成功管理了 18 例具有各种气道病变的患者。对于每个病例，有 7-10 名工作人员在场。严格实施并遵守了适当的个人防护设备方案。在接触经鼻高流量湿化氧疗通气交换后至少一个月内，没有任何工作人员报告出现症状或检测出 2019 年冠状病毒病呈阳性。
在当前大流行期间，通过严格正确使用个人防护设备，经鼻高流量湿化氧疗通气交换可以安全地用于精心挑选的患者，而不会危及耳鼻喉科和麻醉工作人员的健康和安全。
